share_log

EFFECT: Others

EFFECT: Others

EFFECT:其他
美股SEC公告 ·  08/02 06:10

Moomoo AI 已提取核心訊息

eFFECTOR Therapeutics, Inc. has achieved a significant milestone with the Securities and Exchange Commission (SEC) declaring its submission effective as of August 1, 2024. The company's filing, identified by accession number 0001193125-24-188836 and submission type POS AM, has been successfully processed, as indicated by the SEC's Notice of Effectiveness. This development is crucial for eFFECTOR Therapeutics as it pertains to the company's regulatory filings and potential future offerings.
eFFECTOR Therapeutics, Inc. has achieved a significant milestone with the Securities and Exchange Commission (SEC) declaring its submission effective as of August 1, 2024. The company's filing, identified by accession number 0001193125-24-188836 and submission type POS AM, has been successfully processed, as indicated by the SEC's Notice of Effectiveness. This development is crucial for eFFECTOR Therapeutics as it pertains to the company's regulatory filings and potential future offerings.
eFFECTOR Therapeutics, Inc.已在2024年8月1日獲得證券交易委員會(SEC)的重要里程碑。該公司的申報文件編號爲0001193125-24-188836,提交類型爲pos am,已成功處理,如SEC的有效通知所示。對於eFFECTOR Therapeutics而言,這一進展對其監管申報和未來潛在的發行至關重要。
eFFECTOR Therapeutics, Inc.已在2024年8月1日獲得證券交易委員會(SEC)的重要里程碑。該公司的申報文件編號爲0001193125-24-188836,提交類型爲pos am,已成功處理,如SEC的有效通知所示。對於eFFECTOR Therapeutics而言,這一進展對其監管申報和未來潛在的發行至關重要。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息